27 Drydock Avenue
8th Floor
Boston, MA 02210
United States
877 422 5362
https://www.ginkgobioworks.com
Sektor(en): Healthcare
Branche: Biotechnology
Vollzeitmitarbeiter: 1.218
Name | Titel | Zahlen | Ausgeübt | Geburtsjahr |
---|---|---|---|---|
Mr. Mark E. Dmytruk | Chief Financial Officer | 476,5k | N/A | 1972 |
Mr. Thomas Knight Jr. | Founder | N/A | N/A | N/A |
Mr. Austin Che Ph.D. | Founder, Head of Strategy & Treasurer | N/A | N/A | N/A |
Mr. Bartholomew Canton | Founder, CTO & Secretary | N/A | N/A | N/A |
Mr. Steven P. Coen CPA | Chief Accounting Officer | N/A | N/A | N/A |
Karen Tepichin | General Counsel & Secretary | N/A | N/A | N/A |
Ms. Anna Marie Wagner | Senior Vice President of Corporate Development | N/A | N/A | N/A |
Ms. Samantha Sutton | Head of People | N/A | N/A | N/A |
Mr. Joshua Dunn | Head of Design | N/A | N/A | N/A |
Mr. Joaquim Marques | Head of Omics & Analytical Chemistry | N/A | N/A | N/A |
Ginkgo Bioworks Holdings, Inc., together with its subsidiaries, develops platform for cell programming in the United States. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. It serves pharma and biotech, agriculture, industrial and environment, food and nutrition, consumer and technology, and government and defense industries. Ginkgo Bioworks Holdings, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.
Ginkgo Bioworks Holdings, Inc.s ISS Governance QualityScore, Stand 1. Mai 2024, lautet 10. Die grundlegenden Scores sind Audit: 9, Vorstand: 6, Shareholderrechte: 10, Kompensation: 9.